GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (NAS:VCNX) » Definitions » Tax Expense

Vaccinex (Vaccinex) Tax Expense : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Vaccinex Tax Expense?

Vaccinex's tax expense for the months ended in Mar. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Vaccinex Tax Expense Historical Data

The historical data trend for Vaccinex's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaccinex Tax Expense Chart

Vaccinex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial - - - - -

Vaccinex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vaccinex Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaccinex  (NAS:VCNX) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Vaccinex Tax Expense Related Terms

Thank you for viewing the detailed overview of Vaccinex's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaccinex (Vaccinex) Business Description

Traded in Other Exchanges
N/A
Address
1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Executives
Van Strydonck, Gerald E. director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer director, 10 percent owner, officer: President and CEO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Albert Friedberg director, 10 percent owner
Jacob B. Frieberg director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans officer: Chief Operating Officer C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala officer: Chief Commercial Officer 1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk director 1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc. director 1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater director C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian director 1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard officer: SVP, Development 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith officer: SVP, Research & CSO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins officer: SVP & Chief Operating Officer 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620

Vaccinex (Vaccinex) Headlines

From GuruFocus

Vaccinex Announces $3.8 Million Private Placement

By Value_Insider Value_Insider 11-28-2022